Test brain-directed CAR T cells for CNS lymphoma
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This Phase 1 study tests a new type of immune therapy (CAR T cells) placed directly into the fluid around the brain to treat central nervous system (CNS) lymphoma. It mainly looks at safety and how well the treatment can control the lymphoma when other CNS treatments have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can sign informed consent
- You have confirmed primary CNS lymphoma (or specific CNS-only relapse) that can be measured on scans or tests
- Your lymphoma has CD19 found on tumor testing if you previously had CD19-focused treatment
- You have already tried and did not respond to CNS treatments like high-dose methotrexate or high-dose cytarabine
- Your overall health can safely handle the procedure (ECOG 0–2 and you are healthy enough on blood tests and organ checks)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a type of lab-made immune cell therapy (CAR T) using cells called CAR-20/19-T. It is for adults with relapsed or refractory B-cell cancers, aiming to reduce or eliminate lymphoma in people whose disease has come back or not responded to standard treatments.
This Phase 1 study tests a type of immune therapy (CAR T cells) for children with brain tumors that come back or do not respond to standard treatment. The cells are given after chemotherapy that temporarily lowers the body’s immune system, which may help the CAR T cells work better.
This trial tests a new type of CAR T-cell therapy (MB-CART19.1) for people with central nervous system lymphoma (CNSL) that has come back or not responded to treatment. It aims to see if this therapy can help treat the lymphoma in the brain or spinal fluid.
This trial tests a new treatment using specially engineered immune cells from cord blood to target and kill cancer cells in the brain or spine. It is for people whose central nervous system lymphoma has not responded to or has returned after previous treatments.
This trial tests a new treatment called Anbalcabtagene Autoleucel (a type of CAR-T cell therapy) for people whose B-cell lymphoma has come back or not responded to treatment, specifically when it affects the brain or spinal cord. The goal is to see if this therapy can help control the disease.
This early-phase study tests CAR-T cells—immune cells engineered to recognize cancer—for people whose leukemia or lymphoma has spread to the central nervous system (the brain/spinal fluid). It may help shrink or control hard-to-treat (relapsed or refractory) cancers in the brain.
Hear when a new Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.